CG Oncology, Inc. (NASDAQ:CGON – Get Free Report) saw a significant decline in short interest in October. As of October 15th, there was short interest totalling 5,960,000 shares, a decline of 14.5% from the September 30th total of 6,970,000 shares. Based on an average daily volume of 703,100 shares, the days-to-cover ratio is currently 8.5 days. Currently, 14.8% of the shares of the stock are sold short.
Insider Transactions at CG Oncology
In other CG Oncology news, Director Hong Fang Song sold 650,455 shares of the company’s stock in a transaction that occurred on Thursday, August 29th. The stock was sold at an average price of $35.36, for a total value of $23,000,088.80. Following the completion of the sale, the director now owns 586,982 shares of the company’s stock, valued at $20,755,683.52. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Hedge Funds Weigh In On CG Oncology
Institutional investors and hedge funds have recently modified their holdings of the stock. Decheng Capital LLC bought a new stake in CG Oncology in the 1st quarter worth about $239,642,000. Vanguard Group Inc. bought a new stake in CG Oncology in the 1st quarter worth about $97,678,000. BVF Inc. IL bought a new stake in CG Oncology in the 1st quarter worth about $82,716,000. Yu Fan bought a new stake in shares of CG Oncology during the 2nd quarter valued at about $49,828,000. Finally, Janus Henderson Group PLC bought a new stake in shares of CG Oncology during the 1st quarter valued at about $66,757,000. 26.56% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on CG Oncology
CG Oncology Price Performance
CGON traded up $0.12 during trading on Wednesday, reaching $36.31. The stock had a trading volume of 89,484 shares, compared to its average volume of 659,440. The stock’s 50 day moving average is $36.68 and its two-hundred day moving average is $34.71. CG Oncology has a one year low of $25.77 and a one year high of $50.23.
CG Oncology (NASDAQ:CGON – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.28) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.14. The firm had revenue of $0.11 million during the quarter. Research analysts predict that CG Oncology will post -1.47 earnings per share for the current fiscal year.
CG Oncology Company Profile
CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.
Read More
- Five stocks we like better than CG Oncology
- What is a Special Dividend?
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- Comparing and Trading High PE Ratio Stocks
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How Investors Can Find the Best Cheap Dividend Stocks
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for CG Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CG Oncology and related companies with MarketBeat.com's FREE daily email newsletter.